A Phase II Study of Neoadjuvant Chemotherapy Plus Durvalumab (MEDI4736) and Tremelimumab in Advanced-stage Ovarian Cancer (TRU-D)

NCT03899610 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Cancer Stage IIIC
Ovarian Cancer Stage IV

Interventions

DRUG: Neoadjuvant chemotherapy+Durvalumab+Tremelimumab

Sponsor

Yonsei University

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]